|
|
Post by olderteampt on Nov 2, 2017 12:34:36 GMT -5
RRE Funding and Stuart Ellman ring a bell? If your funding One Drop why not MNKD.
|
|
|
|
Post by dreamboatcruise on Nov 2, 2017 12:40:29 GMT -5
RRE Funding and Stuart Ellman ring a bell? If your funding One Drop why not MNKD. Most venture capital firms don't invest in public companies at all. Is it RRE Ventures you're talking about? Why should that ring a bell? |
|
|
|
Post by agedhippie on Nov 2, 2017 12:43:04 GMT -5
RRE Funding and Stuart Ellman ring a bell? If your funding One Drop why not MNKD. Most venture capital firms don't invest in public companies at all. Is it RRE Ventures you're talking about? Why should that ring a bell? Plus Mannkind requires at least an order of magnitude more funding. Mannkind's last round alone is more than twice all of One Drop's funding put together. |
|
|
|
Post by matt on Nov 2, 2017 12:48:03 GMT -5
RRE Funding and Stuart Ellman ring a bell? If your funding One Drop why not MNKD. Afrezza is a pharmaceutical with all its charms and drawbacks. One Drop is a Class II medical device with an entirely different set of charms and drawbacks. While it may seem that there is some synergy there, most pharma investors stick to pharma and most device investors stick to devices. Pfizer, for example, has a large portfolio of drugs for treating cardiac and other metabolic diseases but they totally exited the device business in the late 1980's. Similarly, Medtronic has an outstanding medical device and disposable business but does not develop drugs (although they market a few made by others). The other issue is that One Drop is in business to sell monitors and strips, and from their standpoint it doesn't matter if the insulin used is Afrezza or not. However, their other co-promotion agreements may not fare so well if there is a perception that One Drop is in bed with a competitor. That is why most co-promotion deals are either exclusive between two business partners or totally brand independent, and Afrezza doesn't have the sales volume at present to demand an exclusive relationship. |
|
|
|
Post by olderteampt on Nov 2, 2017 13:02:01 GMT -5
Mankind inhalers are in fact medical devices.
|
|
|
|
Post by od on Nov 3, 2017 11:30:24 GMT -5
About Us
MannKind Corporation (NASDAQ and TASE: MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.
|
|
|
|
Post by invn00b on Nov 3, 2017 11:57:22 GMT -5
Mankind inhalers are in fact medical devices. MNKD inhalers are considered medical devices but are approved as a delivery system within the NDA and do no follow traditional medical device pathways or rules. |
|
